The House of Lords Science and Technology Committee will next week take evidence from medical regulatory bodies as part of their ongoing inquiry into regenerative medicine.
The Committee will hear from representatives of the Human Tissue Authority, the Human Fertilisation and Embryology Authority, the Health Research Authority and others on Tuesday 8 January.
The Committee will ask the witnesses for their response to evidence they have received that the regulatory process for regenerative medicine in the UK is too complex, what is being done to harmonise regulation across Europe and internationally, and what efforts they are making to facilitate early dialogue with companies developing regenerative therapies.
Tuesday 8 January, Committee Room 2A, Palace of Westminster
- Professor Sir Kent Woods, Chief Executive, Medical and Healthcare products Regulation Agency (MHRA)
- Dr Hans-Georg Eichler, Senior Medical Officer, European Medicine Agency
- Dr Janet Wisely, Chief Executive, Health Research Authority
- Peter Thompson, Chief Executive Officer, Human Fertilisation and Embryology Authority (HFEA)
- Alan Clamp, Chief Executive Officer, Human Tissue Authority (HTA)